FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.
What happened
FDA reviewed the company's website, medicaweightloss.com, in March 2026 instead of inspecting a plant. The agency found the site offering compounded semaglutide and tirzepatide products on labels bearing the name "medica weight loss," plus text saying the drugs are FDA-approved and come from an "FDA-approved pharmacy." Compounded drugs are not FDA-approved, and FDA does not approve or license pharmacies or outsourcing facilities.
What FDA found
The product labels shown on the website carry the name "medica weight loss" as if the company made the drugs, which it does not.
FD&C Act section 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)The website says semaglutide's safety and effectiveness are supported by clinical studies and FDA approval, and that tirzepatide is FDA-approved, but compounded drugs are not FDA-approved.
FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website calls the supplier an "FDA-approved pharmacy," a status FDA does not give to pharmacies or outsourcing facilities.
FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The products are "new drugs" not generally recognized as safe and effective, so they must meet the conditions of sections 503A or 503B to be exempt from approval requirements.
FD&C Act sections 503A and 503B [21 U.S.C. §§ 353a, 353b]
What FDA wants
FDA tells the company to email a written response to its Office of Compounding Quality and Compliance within 15 business days, identifying who makes the products, supplying sample labeling, and fixing or removing the false claims. If more time is needed, the company must explain the delay and give a date.
Who should pay attention
- telehealth platforms selling compounded weight-loss drugs
- compounding pharmacies and outsourcing facilities whose products are resold online
- marketing and compliance staff who write drug product web copy
This is a summary. Read the original letter on fda.gov.